SS-31 (elamipretide)
Cardiolipin-targeted mitochondrial peptide.
- Sizes available
- 5mg · 10mg
- Lab certificate (COA)
- Arrives with shipment
· Research-grade only · Not for human consumption · 21+ ·
Mitochondrial-targeted antioxidant (elamipretide). Cardiac / aging clinical stage.
Mechanism · Cardiolipin protector. Stealth Bio Phase 3 (rare cardiomyopathy + aging).
Best for. Not for.
Best for
- Mitochondrial dysfunction related disease (Barth syndrome)
- Cardiolipin protection goals (heart failure / aging)
- Users following the Stealth elamipretide clinical pipeline
Not for
- Active malignancy, pregnancy, or nursing
- MMPOWER-3 missed its primary endpoint in 2021. Efficacy cannot be claimed
- FDA approval delayed (2024 AdCom favorable but FDA delay)
Mechanism, dose, ramp, risk.
- Mechanism
- Targets cardiolipin in inner mitochondrial membrane. Restores energy production.Source · PEPVERA editorial
- Target dose
- 5-10 mg / day subq.Source · PEPVERA editorial
- Ramp
- Begin low, ramp to tolerance.Source · PEPVERA editorial
- Risks
- Limited long-term data.Source · PEPVERA editorial
Compared to its siblings.
SS-31 (elamipretide)
Mitochondrial-targeted antioxidant (elamipretide). Cardiac / aging clinical stage.
Pros
- · Stealth Phase 3 trial data versus MOTS-c and humanin pre-clinical status.
- · Cardiolipin-targeted mechanism distinct from humanin's Bcl-2/Bax anti-apoptotic action.
Cons
- · Not an endogenous mt-encoded peptide like MOTS-c.
- · MMPOWER-3 primary endpoint missed in 2021.
MOTS-c
Mitochondrial peptide. Different mechanism (mt-encoded).
Pros
- · Endogenous mt peptide
Cons
- · Pre-clinical
See MOTS-c →
Humanin
Mitochondrial cytoprotective (Bcl-2/Bax).
Pros
- · Anti-apoptotic
Cons
- · Animal only
See Humanin →
COA per supplier
Published, in-house, or shipment-time
Each supplier declares its own HPLC floor and COA policy. The per-supplier verifier appears on the certificate page; refund and shipping terms vary by supplier and are shown on the supplier listing.
Compare 4 suppliers
| Supplier | Price | COA | Ships | |
|---|---|---|---|---|
| Pure Peptide UKUK | $30$3.00/mg · 10mg | In-house COA | 4 days | Out of stock |
| SwissChemsUS | $41.95$8.39/mg · 5mg | COA with shipment | 3 days | |
| SwissChemsUS | $74.95$7.50/mg · 10mg | COA with shipment | 3 days | |
| Ascension PeptidesUS | $75$7.50/mg · 10mg | Sample COA published | 3 days |
Direct from foundry. Slower than domestic resellers; consistency is the trade. Insulated packaging, tracked from departure to doorstep. Replacement issued on damage.
Week 1–2
5-10 mg / day subq.
Initiation
Week 3–4
5-10 mg / day subq.
Signal emerges
Week 5–8
5-10 mg / day subq.
Hold
Week 9–12
Cycle review
Assess
Draw 20 units.
0.5 mg = 0.20 mL at 2.50 mg/mL. 10.0 doses per vial.
eternal · IV · SwissChems
SS-31 (elamipretide) · 5mg